| Zacks Company Profile for Matinas Biopharma Holdings, Inc. (MTNB : AMEX) |
|
|
| |
| • Company Description |
| Matinas BioPharma is a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its LNC platform technology. The Company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic and orally bioavailable. The Company's lead anti-fungal product candidate, MAT2203, utilizes its proprietary lipid nano-crystal formulation technology for the safe and effective delivery of the broad-spectrum fungicidal agent, amphotericin B. Based on the positive patient clinical data reported in 2017, Matinas is preparing for a potential Phase 2 pivotal trial of MAT2203 for prevention of invasive fungal infections in patients with acute lymphoblastic leukemia.
Number of Employees: 3 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $0.59 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 33,552 shares |
| Shares Outstanding: 6.41 (millions) |
| Market Capitalization: $3.75 (millions) |
| Beta: 1.28 |
| 52 Week High: $3.09 |
| 52 Week Low: $0.47 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-21.97% |
-21.84% |
| 12 Week |
-68.50% |
-69.00% |
| Year To Date |
0.00% |
0.00% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Jerome D. Jabbour - Chairman; Chief Executive Officer & President
Keith A. Kucinski - Chief Financial Officer
Keith Murphy - Director
Edward Neugeboren - Director
Robin L. Smith - Director
|
|
Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 576810303
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/25
Next Expected EPS Date: 04/21/26
|
|
Share - Related Items
Shares Outstanding: 6.41
Most Recent Split Date: 9.00 (0.02:1)
Beta: 1.28
Market Capitalization: $3.75 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $ |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 04/21/26 |
|
|
|
| |
